Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350081 | 1.00 | LMNA (0.37) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL4597901 | 0.86 | LMNA (0.42) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL2148865 | 0.80 | ALDH1A1 (0.47) | ALDH1A1ALOX15TSHR | |
| SCHEMBL15055302 | 0.79 | LMNA (0.37) | LMNANR1I2AHR | |
| SCHEMBL31718366 | 0.79 | LMNA (0.37) | LMNANR1I2AHR | |
| SCHEMBL30696400 | 0.77 | LMNA (0.52) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL11775855 | 0.77 | LMNA (0.52) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL1983684 | 0.75 | NR1I2 (0.47) | LMNAALDH1A1NR1I2AHR | |
| SCHEMBL14438127 | 0.75 | LMNA (0.34) | LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL801870 | 0.72 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024125603-A1 | SHP2 INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-113396147-B | Aromatic heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118206550-A | SHP2 inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117417355-A | Fused heterocyclic compound, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112552294-B | Piperazine heterocyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114751903-B | Nitrogen-containing fused heterocycle SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-111704611-A | Aryl spiro SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2020108590-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | 上海拓界生物医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| CN-111153901-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-8334292-B1 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| EP-0065480-B1 | HALOGENOPYRIMIDINES CONTAINING A SIDE CHAIN, MONOFLUORINATED ON THE PYRIMIDINE NUCLEUS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF REACTIVE DYES | BAYER AG (DE) | 1984-11-14 | — | — | EP | disclosed |
| EP-0065479-A2 | Reactive dyestuffs, process for their preparation and their use in dyeing and printing materials containing hydroxyl groups or nitrogen | BAYER AG (DE) | 1982-11-24 | — | — | EP | disclosed |
| EP-0065480-A1 | Halogenopyrimidines containing a side chain, monofluorinated on the pyrimidine nucleus, process for their preparation and their use in the preparation of reactive dyes | BAYER AG (DE) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | PTPN1, PTPN7, PTPN9 | LMNA 4854/4885ALDH1A1 3157/4885ALOX15 3038/4885 |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | LMNA 3608/4885ALDH1A1 1378/4885ALOX15 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.